Movement Alert｜CSPC PHARMA Rises 3.23% in Regular Trading, Therapeutic mRNA Vaccine Enters Phase II Clinical Trial

Market Focus07-24 09:51

On July 24, CSPC PHARMA rose 3.23% in regular trading, trading at HKD 8.66/share, with turnover of HKD 182 million.

On the news front, the company announced on July 22 that its SYS 6026 injection, a therapeutic mRNA vaccine for treating HPV16 or HPV18-related cervical high-grade squamous intraepithelial lesions, has officially commenced a Phase II clinical trial in China. SYS 6026 is classified as a Category 1 therapeutic biological product, targeting E6 and E7 proteins of HPV16 and HPV18 subtypes. The company had previously received clinical trial approval from China's National Medical Products Administration in November 2024 and has already initiated a Phase I trial evaluating safety and tolerability, with subject recruitment and screening currently underway.

This milestone adds to CSPC PHARMA's recent pipeline momentum, which includes a USD 1.77 billion strategic siRNA collaboration with AstraZeneca announced in early July, a breakthrough therapy designation for SYS6043 in platinum-resistant ovarian cancer, and the Phase II initiation of SYH2070 for mixed hyperlipidaemia.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170184610?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170184610","market":"us","top_or_hot":-1,"title":"Movement Alert｜CSPC PHARMA Rises 3.23% in Regular Trading, Therapeutic mRNA Vaccine Enters Phase II Clinical Trial","media":"Market Focus","content":"<p><p>On July 24, CSPC PHARMA rose 3.23% in regular trading, trading at HKD 8.66/share, with turnover of HKD 182 million.</p><p>On the news front, the company announced on July 22 that its SYS 6026 injection, a therapeutic mRNA vaccine for treating HPV16 or HPV18-related cervical high-grade squamous intraepithelial lesions, has officially commenced a Phase II clinical trial in China. SYS 6026 is classified as a Category 1 therapeutic biological product, targeting E6 and E7 proteins of HPV16 and HPV18 subtypes. The company had previously received clinical trial approval from China's National Medical Products Administration in November 2024 and has already initiated a Phase I trial evaluating safety and tolerability, with subject recruitment and screening currently underway.</p><p>This milestone adds to CSPC PHARMA's recent pipeline momentum, which includes a USD 1.77 billion strategic siRNA collaboration with AstraZeneca announced in early July, a breakthrough therapy designation for SYS6043 in platinum-resistant ovarian cancer, and the Phase II initiation of SYH2070 for mixed hyperlipidaemia.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CSPC PHARMA Rises 3.23% in Regular Trading, Therapeutic mRNA Vaccine Enters Phase II Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CSPC PHARMA Rises 3.23% in Regular Trading, Therapeutic mRNA Vaccine Enters Phase II Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-24 09:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 24, CSPC PHARMA rose 3.23% in regular trading, trading at HKD 8.66/share, with turnover of HKD 182 million.</p><p>On the news front, the company announced on July 22 that its SYS 6026 injection, a therapeutic mRNA vaccine for treating HPV16 or HPV18-related cervical high-grade squamous intraepithelial lesions, has officially commenced a Phase II clinical trial in China. SYS 6026 is classified as a Category 1 therapeutic biological product, targeting E6 and E7 proteins of HPV16 and HPV18 subtypes. The company had previously received clinical trial approval from China's National Medical Products Administration in November 2024 and has already initiated a Phase I trial evaluating safety and tolerability, with subject recruitment and screening currently underway.</p><p>This milestone adds to CSPC PHARMA's recent pipeline momentum, which includes a USD 1.77 billion strategic siRNA collaboration with AstraZeneca announced in early July, a breakthrough therapy designation for SYS6043 in platinum-resistant ovarian cancer, and the Phase II initiation of SYH2070 for mixed hyperlipidaemia.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1170184610","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170184610","pubTimestamp":1784857870,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 24, CSPC PHARMA rose 3.23% in regular trading, trading at HKD 8.66/share, with turnover of HKD 182 million.On the news front, the company announced on July 22 that its SYS 6026 injection, a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"走势预警|石药集团常规交易涨3.23%，治疗性mRNA疫苗进入II期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"On July 24, CSPC PHARMA rose 3.23% in regular trading, trading at HKD 8.66/share, with turnover of HKD 182 million.On the news front, the company announced on July 22 that its SYS 6026 injection, a therapeutic mRNA vaccine for treating HPV16 or HPV18-related cervical high-grade squamous intraepithelial lesions, has officially commenced a Phase II clinical trial in China. SYS 6026 is classified as a Category 1 therapeutic biological product, targeting E6 and E7 proteins of HPV16 and HPV18 subtypes. The company had previously received clinical trial approval from China's National Medical Products Administration in November 2024 and has already initiated a Phase I trial evaluating safety and tolerability, with subject recruitment and screening currently underway.This milestone adds to CSPC PHARMA's recent pipeline momentum, which includes a USD 1.77 billion strategic siRNA collaboration with AstraZeneca announced in early July, a breakthrough therapy designation for SYS6043 in platinum-resistant ovarian cancer, and the Phase II initiation of SYH2070 for mixed hyperlipidaemia.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170184610","isCrawlerRequest":true}